Published in Lancet on July 23, 1988
Complementary medicine: state of the evidence. J R Soc Med (1999) 2.05
Prophylaxis of migraine headache. CMAJ (2010) 1.54
Guidelines for the nonpharmacologic management of migraine in clinical practice. Canadian Headache Society. CMAJ (1998) 1.44
Anxiety over benzodiazepines. Can Fam Physician (1995) 1.35
Treating migraine. BMJ (1989) 1.13
Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs (2004) 1.09
Individuals with a chemical-dependent family member. Does their health care use increase? Can Fam Physician (1995) 1.07
Feverfew (Tanacetum parthenium L.): A systematic review. Pharmacogn Rev (2011) 1.03
Resistance of cholangiocarcinoma cells to parthenolide-induced apoptosis by the excretory-secretory products of Clonorchis sinensis. Parasitol Res (2008) 0.96
Twenty-first century mast cell stabilizers. Br J Pharmacol (2013) 0.89
Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres. Cancer Biol Ther (2012) 0.89
Parthenolide inhibits cancer stem-like side population of nasopharyngeal carcinoma cells via suppression of the NF-κB/COX-2 pathway. Theranostics (2015) 0.85
Clinical pharmacology and therapeutics. Postgrad Med J (1990) 0.84
Targeting radioresistant osteosarcoma cells with parthenolide. J Cell Biochem (2012) 0.84
Feverfew in rheumatoid arthritis: a double blind, placebo controlled study. Ann Rheum Dis (1989) 0.84
Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01. Br J Cancer (2006) 0.84
Cell context-dependent activities of parthenolide in primary and metastatic melanoma cells. Br J Pharmacol (2010) 0.83
Radio-sensitization of the murine osteosarcoma cell line LM8 with parthenolide, a natural inhibitor of NF-κB. Oncol Lett (2011) 0.80
The Feverfew plant-derived compound, parthenolide enhances platelet production and attenuates platelet activation through NF-κB inhibition. Thromb Res (2011) 0.79
Parthenolide induces apoptosis in colitis-associated colon cancer, inhibiting NF-κB signaling. Oncol Lett (2015) 0.77
Natural product HTP screening for antibacterial (E.coli 0157:H7) and anti-inflammatory agents in (LPS from E. coli O111:B4) activated macrophages and microglial cells; focus on sepsis. BMC Complement Altern Med (2016) 0.76
Balsalazide Potentiates Parthenolide-Mediated Inhibition of Nuclear Factor-κB Signaling in HCT116 Human Colorectal Cancer Cells. Intest Res (2015) 0.76
Nutrient- and non-nutrient-based natural health product (NHP) use in adults with mood disorders: prevalence, characteristics and potential for exposure to adverse events. BMC Complement Altern Med (2013) 0.75
Parthenolide promotes apoptotic cell death and inhibits the migration and invasion of SW620 cells. Intest Res (2017) 0.75
Cranberry, feverfew, horse chestnut, and kava. West J Med (1999) 0.75
Dermacase. Papular acrodermatitis of childhood. Can Fam Physician (1995) 0.75
Relative contributions of history-taking, physical examination, and laboratory investigation to diagnosis and management of medical outpatients. Br Med J (1975) 9.18
Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther (1973) 5.23
Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther (1973) 4.40
Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology (1974) 4.32
A randomised trial of home-versus-hospital management for patients with suspected myocardial infarction. Lancet (1978) 4.12
Teichoic acids and membrane function in bacteria. Nature (1970) 3.99
Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther (1973) 3.89
Interim discharge summaries: how are they best delivered to general practitioners? Br Med J (Clin Res Ed) (1987) 3.64
Menopausal flushing: does oestrogen therapy make sense? Lancet (1976) 3.47
Self-poisoning: management of patients in Nottingham, 1976. Br Med J (1978) 3.24
Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin Pharmacol Ther (1974) 2.62
Accumulation and elimination of poliovirus by the eastern oyster. Am J Epidemiol (1966) 2.58
Randomised placebo-controlled trial comparing oxprenolol with disopyramide phosphate in immediate treatment of suspected myocardial infarction. Lancet (1980) 2.53
Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med (1976) 2.33
Randomised trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction. Br Med J (1980) 2.32
Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man. J Clin Invest (1970) 2.29
RNA binding domain of telomerase reverse transcriptase. Mol Cell Biol (2001) 2.27
Effect of a pyrimidopyrimidine derivative on thrombus formation in the rabbit. Nature (1965) 2.19
Is nursing any business of doctors? A simple guide to the "nursing process". Br Med J (Clin Res Ed) (1984) 2.17
Early reporting of myocardial infarction: impact of an experiment in patient education. Br Med J (Clin Res Ed) (1982) 2.11
Isoniazid-associated hepatitis in 114 patients. Gastroenterology (1975) 2.02
Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis. Lancet (1981) 1.92
Platelet reactivity and serum thromboxane B2 production in whole blood in gestational hypertension and pre-eclampsia. Br J Obstet Gynaecol (1991) 1.91
Acetaminophen-induced hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro. J Pharmacol Exp Ther (1973) 1.90
Effect of prostaglandin E1 on platelet behaviour in vitro and in vivo. Br Med J (1967) 1.85
Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet (1985) 1.84
An association between abo blood-group distribution and geographical differences in death-rates. Lancet (1977) 1.81
Effect of dipyridamole on human platelet behaviour. Lancet (1965) 1.79
Plasma glutathione and glutathione disulfide in the rat: regulation and response to oxidative stress. J Pharmacol Exp Ther (1983) 1.79
Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther (1975) 1.75
Oxidation of alpha-methyldopa and other catechols by cytochrome P-450-generated superoxide anion: possible mechanism of methyldopa hepatitis. Mol Pharmacol (1976) 1.73
Dexamethasone in acute stroke. Br Med J (1978) 1.73
Acetaminophen-induced hepatic necrosis. VI. Metabolic disposition of toxic and nontoxic doses of acetaminophen. Pharmacology (1974) 1.70
Is an information booklet for patients leaving hospital helpful and useful? BMJ (1989) 1.68
Antagonism of the antihypertensive action of guanethidine sulfate by desipramine hydrochloride. JAMA (1967) 1.67
What constitutes evidence on the dietary prevention of coronary heart disease? Cosy beliefs or harsh facts? Int J Cardiol (1984) 1.66
The role of the interview in student selection. S Afr Med J (1978) 1.59
Autumn Books: Who needs Clinical Pharmacology? Br Med J (Clin Res Ed) (1984) 1.57
"But will it help my patients with myocardial infarction?" The implications of recent trials for everyday country folk. Br Med J (Clin Res Ed) (1982) 1.55
Effect of aggregating agents on the electrophoretic mobility of human platelets. Br Med J (1966) 1.55
Prevention and diagnosis of venous thrombosis in patients with hip fractures. A survey of current practice. Lancet (1976) 1.52
Blood pressure reduction in elderly: a randomised controlled trial of methyldopa. Br Med J (Clin Res Ed) (1981) 1.52
Ocuurrence of polymers containing N-acetylglucosamine-1-phosphate in bacterial walls. Nature (1968) 1.51
Effect of oestrogens on human platelet behaviour. Lancet (1968) 1.49
Low dose beta blockade in acute stroke ("BEST" trial): an evaluation. Br Med J (Clin Res Ed) (1988) 1.47
Use of isolated perfused organs in hypoxia and ischemia/reperfusion oxidant stress. Methods Enzymol (1990) 1.46
Patients' and general practitioners' satisfaction with information given on discharge from hospital: audit of a new information card. BMJ (1989) 1.45
Acetaminophen-induced hepatic necrosis. V. Correlation of hepatic necrosis, covalent binding and glutathione depletion in hamsters. Pharmacology (1974) 1.43
Progress in hepatology. Metabolic activation of drugs to toxic substances. Gastroenterology (1975) 1.42
The alanine ester content and magnesium binding capacity of walls of Staphylococcus aureus H grown at different pH values. Biochim Biophys Acta (1973) 1.39
Reactive oxygen species during ischemia-reflow injury in isolated perfused rat liver. J Clin Invest (1988) 1.38
Parent and peer attachment in early adolescent depression. J Abnorm Child Psychol (1990) 1.38
Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science (1976) 1.38
Magnetization transfer and multicomponent T2 relaxation measurements with histopathologic correlation in an experimental model of MS. J Magn Reson Imaging (2000) 1.37
Anticoagulants in coronary heart disease--retrospect and prospect. Lancet (1981) 1.36
A comparison of the abilities of acetylsalicylic acid, flurbiprofen and indomethacin to inhibit the release reaction and prostaglandin synthesis in human blood platelets. Br J Pharmacol (1979) 1.34
Platelet behaviour and drugs used in cardiovascular disease. Cardiovasc Res (1967) 1.32
The distribution of the glucosyl substituents along the chain of the teichoic acid in walls of Lactobacillus buchneri N.C.I.B. 8007. Biochem J (1969) 1.31
Abnormalities in platelet behaviour in acute illnesses. Br Med J (1966) 1.31
Treatment of high blood pressure: should clinical practice be based on results of clinical trials? Br Med J (Clin Res Ed) (1986) 1.31
Mechanism of action of N-acetylcysteine in the protection against the hepatotoxicity of acetaminophen in rats in vivo. J Clin Invest (1983) 1.31
Nature of the transferable factor which causes abnormal platelet behaviour in vascular disease. Lancet (1967) 1.27
Clinical management of venous thrombo-embolism. Br Med Bull (1978) 1.26
Contribution of atenolol, bendrofluazide, and hydrallazine to management of severe hypertension. Br Med J (1977) 1.26
Organisation of the external region of the starch granule as determined by infrared spectroscopy. Int J Biol Macromol (2002) 1.26
Guanethidine and related agents. I. Mechanism of the selective blockade of adrenergic neurons and its antagonism by drugs. J Pharmacol Exp Ther (1970) 1.26
The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol (2000) 1.26
Timolol after myocardial infarction: an answer or a new set of questions? Br Med J (Clin Res Ed) (1981) 1.25
Platelet aggregation in whole blood determined using the Ultra-Flo 100 Platelet Counter. Thromb Haemost (1982) 1.25
Pilot studies on recombinant cold-adapted live type A and B influenza virus vaccines. J Infect Dis (1977) 1.25
Effects of N-acetylcysteine on acetaminophen covalent binding and hepatic necrosis in mice. J Pharmacol Exp Ther (1985) 1.24
Hepatic glutathione homeostasis in the rat: efflux accounts for glutathione turnover. Hepatology (1984) 1.23
Developments in understanding the basis of cooked-rice texture. Crit Rev Food Sci Nutr (2000) 1.23
Effect of oral contraceptive agents on platelets and plasma-phospholipids. Lancet (1968) 1.23
Oestrogen treatment for menopausal flushing. Br Med J (1977) 1.21
Further studies on the glycerol teichoic acid of walls of Staphylococcus lactis I3. Location of the phosphodiester groups and their susceptibility to hydrolysis with alkali. Biochem J (1971) 1.20
Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour. Thromb Res (1980) 1.19
The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler (2007) 1.18
Biliary excretion of glutathione and glutathione disulfide in the rat. Regulation and response to oxidative stress. J Clin Invest (1984) 1.18
Molecular basis for several drug-induced nephropathies. Am J Med (1977) 1.18
Impact of particle size distribution on rheological and textural properties of chocolate models with reduced fat content. J Food Sci (2007) 1.18
Acute pulmonary injury in rats by nitrofurantoin and modification by vitamin E, dietary fat, and oxygen. Am Rev Respir Dis (1979) 1.18
Neonatal platelet reactivity and serum thromboxane B2 production in whole blood: the effect of maternal low dose aspirin. Br J Obstet Gynaecol (1994) 1.18
Evidence that acetaminophen and N-hydroxyacetaminophen form a common arylating intermediate, N-acetyl-p-benzoquinoneimine. Mol Pharmacol (1980) 1.18
Secondary prevention of myocardial infarction--the present state of the ART. Br Med J (1980) 1.16
Intravenous urography in the management of acute retention. Lancet (1977) 1.16
Effectiveness of speech therapy for aphasic stroke patients. A randomised controlled trial. Lancet (1984) 1.16
Effects of chronic central nervous system administration of agouti-related protein in pair-fed animals. Diabetes (2001) 1.15
Effect of glass contact on the electrophoretic mobility of human blood platelets. Nature (1966) 1.14
A placebo-controlled dose-response study of the reactogenicity and immunogenicity of a cold-adapted recombinant A/Victoria/3/75 (H3N2) live influenza virus candidate vaccine in healthy volunteers. Dev Biol Stand (1978) 1.13
The variability of human platelet aggregation. J Atheroscler Res (1967) 1.13
Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. Chest (1975) 1.12
Preventing venous thromboembolism in elderly patients with hip fractures: studies of low-dose heparin, dipyridamole, aspirin, and flurbiprofen. Br Med J (1977) 1.10
The influence of psychosocial factors on survival after myocardial infarction. Public Health (1993) 1.10
The influence of red blood-cells on platelet adhesiveness. Lancet (1966) 1.09
Adenosine diphosphate induced platelet aggregation and release reaction in heparinized platelet rich plasma and the influence of added citrate. Br J Haematol (1977) 1.08